|EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update|
JS Smolen, R Landewé, FC Breedveld, M Buch, G Burmester, ...
Annals of the rheumatic diseases 73 (3), 492-509, 2014
|Classification criteria for Sjögren’s syndrome|
C Vitali, N Del Papa
Sjögren's Syndrome, 47-60, 2016
|Genetics of rheumatoid arthritis contributes to biology and drug discovery|
Y Okada, D Wu, G Trynka, T Raj, C Terao, K Ikari, Y Kochi, K Ohmura, ...
Nature 506 (7488), 376-381, 2014
|Regression of splenic lymphoma with villous lymphocytes after treatment of hepatitis C virus infection|
O Hermine, F Lefrère, JP Bronowicki, X Mariette, K Jondeau, ...
New England Journal of Medicine 347 (2), 89-94, 2002
|2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: a consensus and data-driven methodology …|
CH Shiboski, SC Shiboski, R Seror, LA Criswell, M Labetoulle, ...
Annals of the rheumatic diseases 76 (1), 9-16, 2017
|Risk of tuberculosis is higher with anti–tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: The three‐year prospective …|
F Tubach, D Salmon, P Ravaud, Y Allanore, P Goupille, M Bréban, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2009
|High-dose therapy and autologous peripheral blood stem cell transplantation in multiple myeloma: up-front or rescue treatment? Results of a multicenter sequential randomized …|
JP Fermand, P Ravaud, S Chevret, M Divine, V Leblond, C Belanger, ...
Blood, The Journal of the American Society of Hematology 92 (9), 3131-3136, 1998
|EULAR Sjögren's syndrome disease activity index: development of a consensus systemic disease activity index for primary Sjögren's syndrome|
R Seror, P Ravaud, SJ Bowman, G Baron, A Tzioufas, E Theander, ...
Annals of the rheumatic diseases 69 (6), 1103-1109, 2010
|The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome|
X Mariette, S Roux, J Zhang, D Bengoufa, F Lavie, T Zhou, R Kimberly
Annals of the rheumatic diseases 62 (2), 168-171, 2003
|Randomized phase II trial of denosumab in patients with bone metastases from prostate cancer, breast cancer, or other neoplasms after intravenous bisphosphonates|
K Fizazi, A Lipton, X Mariette, JJ Body, Y Rahim, JR Gralow, G Gao, L Wu, ...
Journal of Clinical Oncology 27 (10), 1564-1571, 2009
|Activation of IFN pathways and plasmacytoid dendritic cell recruitment in target organs of primary Sjögren’s syndrome|
JE Gottenberg, N Cagnard, C Lucchesi, F Letourneur, S Mistou, T Lazure, ...
Proceedings of the National Academy of Sciences 103 (8), 2770-2775, 2006
|Treat-to-target in systemic lupus erythematosus: recommendations from an international task force|
RF Van Vollenhoven, M Mosca, G Bertsias, D Isenberg, A Kuhn, ...
Annals of the rheumatic diseases 73 (6), 958-967, 2014
|Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases|
JE Gottenberg, L Guillevin, O Lambotte, B Combe, Y Allanore, ...
Annals of the rheumatic diseases 64 (6), 913-920, 2005
|Inefficacy of infliximab in primary Sjögren's syndrome: results of the randomized, controlled Trial of Remicade in Primary Sjögren's Syndrome (TRIPSS)|
X Mariette, P Ravaud, S Steinfeld, G Baron, J Goetz, E Hachulla, ...
Arthritis & Rheumatism: Official Journal of the American College of …, 2004
|Lymphomas in rheumatoid arthritis patients treated with methotrexate: a 3-year prospective study in France|
X Mariette, D Cazals-Hatem, J Warszawki, F Liote, N Balandraud, J Sibilia
Blood 99 (11), 3909-3915, 2002
|A phase I study of AMGN‐0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases|
JJ Body, P Greipp, RE Coleman, T Facon, F Geurs, JP Fermand, ...
Cancer: Interdisciplinary International Journal of the American Cancer …, 2003
|2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus|
M Aringer, K Costenbader, D Daikh, R Brinks, M Mosca, ...
Arthritis & rheumatology 71 (9), 1400-1412, 2019
|High-dose therapy and autologous blood stem-cell transplantation compared with conventional treatment in myeloma patients aged 55 to 65 years: long-term results of a randomized …|
JP Fermand, S Katsahian, M Divine, V Leblond, F Dreyfus, M Macro, ...
Journal of clinical oncology 23 (36), 9227-9233, 2005
|Updated consensus statement on the use of rituximab in patients with rheumatoid arthritis|
MH Buch, JS Smolen, N Betteridge, FC Breedveld, G Burmester, T Dörner, ...
Annals of the rheumatic diseases 70 (6), 909-920, 2011
|Systemic lupus erythematosus induced by anti-tumour necrosis factor alpha therapy: a French national survey|
M De Bandt, J Sibilia, X Le Loët, S Prouzeau, B Fautrel, C Marcelli, ...
Arthritis research & therapy 7 (3), 1-7, 2005